La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for chronic organ failure and cancer. Product Portfolio The company has a product portfolio consisting of both development-stage and discovery-stage products. Its drug development efforts are focused on two product candidates, GCS-100 and LJPC-501. GCS-100 GCS-100 targets the galectin-3 protein, which, when overproduced by the human body, has been associated with chronic organ failure and cancer. In January 2013, the company initiated a Phase 1/2 clinical trial with GCS-100 for the treatment of chronic kidney disease. GCS-100 also has the potential to treat various forms of chronic liver disease also characterized by tissue fibrosis. By modulating galectin-3’s effects on cell survival, blood vessel growth and the immune response, GCS-100 has the potential to treat various forms of cancer. LJPC-501 LJPC-501 is a peptide agonist of the renin-angiotensin system, which is designed to help restore kidney function in patients with hepatorenal syndrome (HRS). The company plans to file an Investigational New Drug Application with the Food and Drug Administration for LJPC-501 in the third quarter of 2013 and initiate a Phase 1 clinical trial in HRS by the end of 2013. Other Product Candidates In addition to GCS-100 and LJPC-501, the company has various product candidates in the early development stage. These product candidates include LJPC-101, a subcutaneous formulation of GCS-100; LJPC-201, an oral galectin-3 inhibitor; and LJPC-301, a monoclonal antibody designed to neutralize galectin-3. Patents and Proprietary Technologies As of March 22, 2013, the company had three issued patents, one allowed patent and three pending patent applications in the United States; two pending patent applications in Canada; and one pending patent application in Europe. The issued and allowed patents provide, and if issued, the pending patent applications would provide, protection for its lead drug candidate GCS-100, including claims for compositions of modified pectin solutions, methods for manufacturing modified pectins and modified pectin solutions, and compositions and uses of galectin antagonists. The issued and allowed patents expire between 2025 and 2028. Government Regulation In the United States, the Federal Food, Drug and Cosmetic Act and the Public Health Service Act govern the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion, and distribution of the company’s drug candidates. History La Jolla Pharmaceutical Company was founded in 1989. The company was incorporated in 1989 in Delaware and reincorporated in California in 2012.
la jolla pharmaceutical co (LJPC:OTC BB)
4660 La Jolla Village Drive
San Diego, CA 92122
|No competitor information is available for LJPC.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Post a JobJobs
- New York, NY | JPMorgan ChasePosted: Dec 06
- Alexandria, VA |Posted: Dec 06
- Detroit, MI | Wayne State UniversityPosted: Nov 26
- New York, NY | AGORAPosted: Nov 25
Sponsored Financial Commentaries
To contact LA JOLLA PHARMACEUTICAL CO, please visit www.ljpc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.